These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. Meng H; Chen R; Li W; Xu L; Xu L Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507 [TBL] [Abstract][Full Text] [Related]
3. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452 [TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia. Klumper E; Giaccone G; Pieters R; Broekema G; van Ark-Otte J; van Wering ER; Kaspers GJ; Veerman AJ Leukemia; 1995 Oct; 9(10):1653-60. PubMed ID: 7564505 [TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920 [TBL] [Abstract][Full Text] [Related]
6. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients. Wang YH; Takanashi M; Tsuji K; Tanaka N; Shiseki M; Mori N; Motoji T Leuk Res; 2009 Jul; 33(7):902-7. PubMed ID: 19185918 [TBL] [Abstract][Full Text] [Related]
7. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769 [TBL] [Abstract][Full Text] [Related]
8. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533 [TBL] [Abstract][Full Text] [Related]
9. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes. Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232 [TBL] [Abstract][Full Text] [Related]
10. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Mueller RE; Parkes RK; Andrulis I; O'Malley FP Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790 [TBL] [Abstract][Full Text] [Related]
11. Topo IIα gene alterations correlated with survival in patients with diffuse large B-cell lymphoma. Chen Z; Wang J; Zhang H; Liu D; Li Y; Xu Y; Tan D; Chen D; Zhao X; Wang G Eur J Clin Invest; 2012 Mar; 42(3):310-20. PubMed ID: 21880040 [TBL] [Abstract][Full Text] [Related]
13. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009 [TBL] [Abstract][Full Text] [Related]
14. Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864 [TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Coon JS; Marcus E; Gupta-Burt S; Seelig S; Jacobson K; Chen S; Renta V; Fronda G; Preisler HD Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114 [TBL] [Abstract][Full Text] [Related]
16. [Preliminary study of gene expression profile associated with risk classification of childhood patients with acute lymphoblastic leukemia]. Wang JL; Chai YH; Ji ZH; Shao XJ; Huang YP Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):29-33. PubMed ID: 21429398 [TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837 [TBL] [Abstract][Full Text] [Related]
18. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha. Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052 [TBL] [Abstract][Full Text] [Related]
19. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085 [TBL] [Abstract][Full Text] [Related]
20. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. Hof J; Krentz S; van Schewick C; Körner G; Shalapour S; Rhein P; Karawajew L; Ludwig WD; Seeger K; Henze G; von Stackelberg A; Hagemeier C; Eckert C; Kirschner-Schwabe R J Clin Oncol; 2011 Aug; 29(23):3185-93. PubMed ID: 21747090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]